Revance affirms guidance after Q2 results

|About: Revance Therapeutics, ... (RVNC)|By:, SA News Editor

Revance Therapeutics (RVNC -2.2%) Q2 results: Revenues: $75K (unch); Operating Expenses: $13.0M (+13.5%); Net Loss: ($13.3M) (-12.7%); Loss Per Share: ($0.69) (+98.4%); Quick Assets: $203.3M (+999%).

2014 Guidance: operating expenses: $55M - 60M; cash burn: $75M - 85M.